Amgen to Acquire Five Prime Therapeutics for $1.9 Billion
Amgen Inc. plans to acquire Bay Area biotech company Five Prime Therapeutics for $1.9 billion in cash, or $38 per share.
More from California Business
North California Record
Following state appellate ruling involving ADA claims, further relief urged at federal level
California Business
•
Dec 5, 2022
FresnoBee | Business
Here's How to Keep Winter Utility Bills Down as Energy Costs Rise
California Business
•
Dec 5, 2022
East Bay Times | Business
Released Twitter emails show how employees debated how to handle 2020 New York Post Hunter Biden story
California Business
•
Dec 5, 2022